With the first medical therapy approved and systems like CRISPR-Cas showing up in complex cells, there’s a lot going on in the genome editing field. Here’s our primer.
OPINION: A massive bias in medical studies toward men of European origin means that genetic variants in understudied populations don’t get the focus they deserve
Polygenic risk scores — a patient’s chance, based on tiny DNA variants, of developing cardiovascular disease, breast cancer and more — are coming to clinics. But there are kinks to iron out and accuracy remains an issue.
A scientist whose work was key to identifying, studying and finding treatments for this life-threatening virus discusses the scientific journey and challenges that persist
The pandemic put the technology, long in development, to the test. Here’s a look at the status of its application to cancer and when it might reach patients.
Bt crops keep many agricultural pests at bay and have drastically reduced the use of pesticides. But scientists warn that these valuable tools are in jeopardy due to overuse and abuse.
Genetic conditions like Dravet syndrome, which causes severe childhood epilepsy, are hard to tackle with traditional gene therapy. New approaches in the works include using antisense therapy to boost mRNA splicing.
Amyloid plaque can build up in body organs other than the brain. The resulting diseases — AL amyloidosis, ATTR amyloidosis and more — cause much suffering.
